Magesh Ramasamy
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Magesh Ramasamy has a total of 122 co-authors. Here are the top co-authors by number of shared publications:
- C. George Priya Doss
Department of Integrative Biology, School of Biosciences and Technology, Vellore Institute of Technology (VIT), Vellore, Tamil Nadu, India
13 shared publications - D. Thirumal Kumar
Faculty of Allied Health Sciences, Meenakshi Academy of Higher Education and Research, Chennai, Tamil Nadu, India
7 shared publications D. Thirumal Kumar
Meenakshi Academy of Higher Education and Research
5 shared publicationsMadhana Priya N
Department of Biotechnology, Faculty of Biomedical Sciences & Technology
5 shared publicationsN. Madhana Priya
Department of Biotechnology, Faculty of Biomedical Sciences & Technology, Sri Ramachandra Institute of Higher Education and Research (DU)
5 shared publicationsSidharth Kumar N
Computational Biology Lab, Department of Biotechnology, Faculty of Biomedical Sciences & Technology, Sri Ramachandra Institute of Higher Education & Research
5 shared publications
Latest Publications
- Open Access
- 17 October 2026
- Published by Springer Nature in Discover Oncology
Mechanistic integration of genetic alterations, PTM signaling, and tumor microenvironment remodeling in pancreatic ductal adenocarcinoma
- 17 October 2026
- Published by Springer Nature in Discover Oncology
Open AccessMechanistic integration of genetic alterations, PTM signaling, and tumor microenvironment remodeling in pancreatic ductal adenocarcinoma
- 21 September 2026
- Published by Wiley in ChemistrySelect
- Vol. 11 (36)
Computational Elucidation of Potent Ligands Targeting Recalcitrant ALK G1202R‐Associated Double Mutations Underlying Lorlatinib Resistance
Targeting ALK has become a viable therapeutic strategy in non‐small cell lung cancer (NSCLC) following the discovery of the EML4‐ALK fusion. Several inhibitors were developed which improved the patient's outcomes; however, the emergence of drug resistance limits the treatment and poses significant challenges. The sequential use of inhibitors led to the development of compound mutations, predominantly G1202R‐based double mutations. In this study, we analyzed two highly recalcitrant G1202R‐paired double mutations – G1202R+L1196M and G1202R+S1206Y detected in EML4‐ALK variant 3 patients in cis following lorlatinib therapy. This study employs an integrated approach, including virtual screening, ADMET analysis, molecular docking, and simulations, to identify potential lead compounds. We identified two compounds, CID 118002992 and CID 155425575, from virtual screening with better characteristics. Molecular docking revealed that CID 155425575 exhibited stronger binding affinity with G1202R+L1196M (−9.33 kcal/mol) and G1202R+S1206Y (−9.29 kcal/mol). MD simulations were performed for 200 ns to investigate the stability and conformational changes of ALK double mutations and WT‐ALK in the presence of ligands. Notably, CID 155425575 showed enhanced structural stability and compactness and demonstrated the most favorable binding free energies (−103.250 ± 15.928 kJ/mol and −95.886 ± 11.813 kJ/mol), emerging as a promising lead candidate against the G1202R‐paired double mutations.
- 21 September 2026
- Published by Wiley in ChemistrySelect
- Vol. 11 (36)
Computational Elucidation of Potent Ligands Targeting Recalcitrant ALK G1202R‐Associated Double Mutations Underlying Lorlatinib Resistance
Targeting ALK has become a viable therapeutic strategy in non‐small cell lung cancer (NSCLC) following the discovery of the EML4‐ALK fusion. Several inhibitors were developed which improved the patient's outcomes; however, the emergence of drug resistance limits the treatment and poses significant challenges. The sequential use of inhibitors led to the development of compound mutations, predominantly G1202R‐based double mutations. In this study, we analyzed two highly recalcitrant G1202R‐paired double mutations – G1202R+L1196M and G1202R+S1206Y detected in EML4‐ALK variant 3 patients in cis following lorlatinib therapy. This study employs an integrated approach, including virtual screening, ADMET analysis, molecular docking, and simulations, to identify potential lead compounds. We identified two compounds, CID 118002992 and CID 155425575, from virtual screening with better characteristics. Molecular docking revealed that CID 155425575 exhibited stronger binding affinity with G1202R+L1196M (−9.33 kcal/mol) and G1202R+S1206Y (−9.29 kcal/mol). MD simulations were performed for 200 ns to investigate the stability and conformational changes of ALK double mutations and WT‐ALK in the presence of ligands. Notably, CID 155425575 showed enhanced structural stability and compactness and demonstrated the most favorable binding free energies (−103.250 ± 15.928 kJ/mol and −95.886 ± 11.813 kJ/mol), emerging as a promising lead candidate against the G1202R‐paired double mutations.
- Open Access
- 11 August 2026
- Published by Frontiers Media SA in Frontiers in Oncology
- Vol. 16, 1950779
Correction: Molecular and microenvironmental drivers of malignant transformation from oral potentially malignant disorders to oral squamous cell carcinoma
Correction on: V. V, R. S, S. S and R. M (2026) Molecular and microenvironmental drivers of malignant transformation from oral potentially malignant disorders to oral squamous cell carcinoma. Front. Oncol. 16:1856931. doi: 10.3389/fonc.2026.1856931 The funder [SRM Institute of Science and Technology, Kattankulathur], to [Sundaresan S] was erroneously omitted. The city of affiliation 2 was erroneously written as "Chennai". Affiliation 2 has been corrected to "Division of Medical Research, SRM MCH and RC, SRM IST, Kattankulathur, Tamil Nadu, India".The original version of this article has been updated.
- 11 August 2026
- Published by Frontiers Media SA in Frontiers in Oncology
- Vol. 16, 1950779
Open AccessCorrection: Molecular and microenvironmental drivers of malignant transformation from oral potentially malignant disorders to oral squamous cell carcinoma
Correction on: V. V, R. S, S. S and R. M (2026) Molecular and microenvironmental drivers of malignant transformation from oral potentially malignant disorders to oral squamous cell carcinoma. Front. Oncol. 16:1856931. doi: 10.3389/fonc.2026.1856931 The funder [SRM Institute of Science and Technology, Kattankulathur], to [Sundaresan S] was erroneously omitted. The city of affiliation 2 was erroneously written as "Chennai". Affiliation 2 has been corrected to "Division of Medical Research, SRM MCH and RC, SRM IST, Kattankulathur, Tamil Nadu, India".The original version of this article has been updated.
- Open Access
- 24 July 2026
- Published by Frontiers Media SA in Frontiers in Bioinformatics
- Vol. 6, 1875897
Functional restoration of conformational (R175H) and contact (R273H) mutant p53 by Bacillus-derived Hydroxymycotrienin A in non-small cell lung cancer: a computational approach
Introduction: The TP53 mutations in Non-Small Cell Lung Cancer (NSCLC) remain a formidable clinical challenge. Current strategies, using the covalent binder APR-246, are limited by off-target toxicity and resistance. Methods: This study screens 1,580 Bacillus -derived metabolites to identify novel non-covalent pharmacological chaperones for native, conformational (R175H), and contact (R273H) p53 mutants. Virtual screening, ADMET profiling, molecular docking, extended 500 ns Molecular Dynamics (MD) simulations and Principal Component Analysis, against experimental anti-cancer drug APR-246, and top hit compounds. Results: Hydroxymycotrienin A emerged as the potential candidate, demonstrating thermodynamic superiority with binding affinities of −6.63 kcal/mol (R175H) and −6.57 kcal/mol (R273H), demonstrated significant superior non covalent docking affinity compared to APR-246 parent scaffold (approximately −3.5 kcal/mol) in the mutated p53 protein, suggesting a direct pharmacological chaperone activity. Unlike the covalent alkylating mechanism of APR-246, Hydroxymycotrienin A utilizes a non-covalent network to chaperone the mutant p53. MD simulations revealed that Hydroxymycotrienin A acted as a structural stabilizer for the conformational mutant R175H by suppressing atomic fluctuations within the L2 loop and reducing overall structural deviations. In the contact mutant R273H, the ligand stabilized the DNA-binding interface while maintaining favorable conformational dynamics without introducing steric clashes. Discussion: ADMET profiling predicts high bioavailability and a non-toxic safety profile, characterizing Hydroxymycotrienin A as a promising, bioavailable ‘privileged scaffold’ that offers a non-covalent therapeutic strategy for NSCLC. By restoring p53 function, this study addresses Sustainable Development Goals Target 3.4 to reduce premature mortality from non-communicable diseases. However, future in vitro and in vivo studies are required to validate the efficacy of these compounds.
- 24 July 2026
- Published by Frontiers Media SA in Frontiers in Bioinformatics
- Vol. 6, 1875897
Open AccessFunctional restoration of conformational (R175H) and contact (R273H) mutant p53 by Bacillus-derived Hydroxymycotrienin A in non-small cell lung cancer: a computational approach
Introduction: The TP53 mutations in Non-Small Cell Lung Cancer (NSCLC) remain a formidable clinical challenge. Current strategies, using the covalent binder APR-246, are limited by off-target toxicity and resistance. Methods: This study screens 1,580 Bacillus -derived metabolites to identify novel non-covalent pharmacological chaperones for native, conformational (R175H), and contact (R273H) p53 mutants. Virtual screening, ADMET profiling, molecular docking, extended 500 ns Molecular Dynamics (MD) simulations and Principal Component Analysis, against experimental anti-cancer drug APR-246, and top hit compounds. Results: Hydroxymycotrienin A emerged as the potential candidate, demonstrating thermodynamic superiority with binding affinities of −6.63 kcal/mol (R175H) and −6.57 kcal/mol (R273H), demonstrated significant superior non covalent docking affinity compared to APR-246 parent scaffold (approximately −3.5 kcal/mol) in the mutated p53 protein, suggesting a direct pharmacological chaperone activity. Unlike the covalent alkylating mechanism of APR-246, Hydroxymycotrienin A utilizes a non-covalent network to chaperone the mutant p53. MD simulations revealed that Hydroxymycotrienin A acted as a structural stabilizer for the conformational mutant R175H by suppressing atomic fluctuations within the L2 loop and reducing overall structural deviations. In the contact mutant R273H, the ligand stabilized the DNA-binding interface while maintaining favorable conformational dynamics without introducing steric clashes. Discussion: ADMET profiling predicts high bioavailability and a non-toxic safety profile, characterizing Hydroxymycotrienin A as a promising, bioavailable ‘privileged scaffold’ that offers a non-covalent therapeutic strategy for NSCLC. By restoring p53 function, this study addresses Sustainable Development Goals Target 3.4 to reduce premature mortality from non-communicable diseases. However, future in vitro and in vivo studies are required to validate the efficacy of these compounds.
- Open Access
- 3 June 2026
- Published by Frontiers Media SA in Frontiers in Oncology
- Vol. 16, 1856931
Molecular and microenvironmental drivers of malignant transformation from oral potentially malignant disorders to oral squamous cell carcinoma
Oral potentially malignant disorders (OPMDs) comprise a diverse group of oral mucosal lesions with a variable but significant risk of progression to oral squamous cell carcinoma (OSCC). However, predicting malignant transformation remains a major clinical challenge due to the limited reliability of conventional histopathological grading and the inherent biological heterogeneity of these lesions. Increasing evidence indicates that OPMD progression is a dynamic, multistep process driven by the convergence of molecular alterations and microenvironmental remodeling. This review synthesizes current knowledge on the key mechanisms underlying OPMD-to-OSCC transformation, focusing on the interplay between genomic instability, epigenetic dysregulation, chronic inflammation, and tumor microenvironment evolution. Dysregulation of critical signaling pathways, including TGF-β, PI3K/AKT, MAPK, Wnt/β-catenin, and NF-κB, contributes to epithelial plasticity, immune evasion, fibrosis, and sustained oncogenic signaling. Special attention is given to oral submucous fibrosis as a high-risk model, highlighting the role of extracellular matrix stiffening and mechanotransduction pathways such as YAP/TAZ in promoting malignant progression. The limitations of morphology-based diagnostics underscore the need for molecularly informed risk assessment in modern healthcare. Emerging biomarkers including genetic, epigenetic, transcriptomic, proteomic, metabolomic, and exosomal signatures offer promising tools for early detection and stratification of high-risk lesions. Furthermore, integration of multi-omics data with artificial intelligence based predictive models holds significant potential for advancing precision oncology in oral cancer. Collectively, this review supports an evolutionary shift in understanding OPMDs as dynamic and evolving biological systems rather than static precursor lesions. Elucidating the molecular and microenvironmental convergence driving malignant transformation provides a foundation for improved early detection, risk prediction, and development of targeted preventive and therapeutic strategies in OSCC.
- 3 June 2026
- Published by Frontiers Media SA in Frontiers in Oncology
- Vol. 16, 1856931
Open AccessMolecular and microenvironmental drivers of malignant transformation from oral potentially malignant disorders to oral squamous cell carcinoma
Oral potentially malignant disorders (OPMDs) comprise a diverse group of oral mucosal lesions with a variable but significant risk of progression to oral squamous cell carcinoma (OSCC). However, predicting malignant transformation remains a major clinical challenge due to the limited reliability of conventional histopathological grading and the inherent biological heterogeneity of these lesions. Increasing evidence indicates that OPMD progression is a dynamic, multistep process driven by the convergence of molecular alterations and microenvironmental remodeling. This review synthesizes current knowledge on the key mechanisms underlying OPMD-to-OSCC transformation, focusing on the interplay between genomic instability, epigenetic dysregulation, chronic inflammation, and tumor microenvironment evolution. Dysregulation of critical signaling pathways, including TGF-β, PI3K/AKT, MAPK, Wnt/β-catenin, and NF-κB, contributes to epithelial plasticity, immune evasion, fibrosis, and sustained oncogenic signaling. Special attention is given to oral submucous fibrosis as a high-risk model, highlighting the role of extracellular matrix stiffening and mechanotransduction pathways such as YAP/TAZ in promoting malignant progression. The limitations of morphology-based diagnostics underscore the need for molecularly informed risk assessment in modern healthcare. Emerging biomarkers including genetic, epigenetic, transcriptomic, proteomic, metabolomic, and exosomal signatures offer promising tools for early detection and stratification of high-risk lesions. Furthermore, integration of multi-omics data with artificial intelligence based predictive models holds significant potential for advancing precision oncology in oral cancer. Collectively, this review supports an evolutionary shift in understanding OPMDs as dynamic and evolving biological systems rather than static precursor lesions. Elucidating the molecular and microenvironmental convergence driving malignant transformation provides a foundation for improved early detection, risk prediction, and development of targeted preventive and therapeutic strategies in OSCC.
- Open Access
- 21 May 2026
- Published by Frontiers Media SA in Frontiers in Bioinformatics
- Vol. 6, 1815548
Integrative transcriptomics and structure-based screening identifies Phyllanthus amarus phytocompounds as potential WNT5A modulators in ovarian cancer
Introduction: Ovarian cancer is one of the most lethal gynecological malignancies, largely due to its asymptomatic onset, heterogeneous molecular landscape, and frequent late-stage diagnosis. Identifying key oncogenic drivers and novel therapeutic candidates is important for understanding disease progression and guiding future research efforts. Methods: An integrative computational pipeline was employed to identify differentially expressed genes prioritize a candidate target, and screen plant compounds for anticancer potential. Transcriptomic datasets (GSE14407, GSE18520, and GSE26712) were retrieved from Gene Expression Omnibus and analyzed using GEO2R. The three-dimensional structure of WNT5A was obtained from AlphaFold. GC–MS profiling of Phyllanthus amarus Schumach. and Thonn. Identified phytocompounds for virtual screening, followed by molecular docking, ADME, and toxicity prediction. Molecular dynamics simulations, Free Energy Landscape and Dynamic Cross-Correlation Matrix analyses were performed. Further, Free energy perturbation (FEP) calculations were performed to estimate relative binding free energies across alchemical λ states. Results: A total of 103 consistently upregulated genes were identified, among which WNT5A emerged as a key regulator associated with tumor progression, metastasis, and chemoresistance. Enrichment analysis indicated involvement in mesenchymal development, extracellular matrix organization, and receptor-mediated signaling. GC–MS identified 48 compounds, and docking revealed several ligands with favorable interactions with WNT5A . MD simulations supported the structural stability of selected complexes, while FEL and DCCM analyses indicated stable conformational states and ligand-influenced residue dynamics. The FEP-derived free energy estimates further supported the stability and favorable binding of selected ligands toward WNT5A. These results enhance confidence in the computational predictions and complement the MD and docking analyses. Discussion: This integrative in silico framework highlights WNT5A as a potential therapeutic target and identifies bioactive compounds from P. amarus as candidates for further investigation. These findings provide preliminary computational insights and warrant experimental validation to improve treatment outcomes in healthcare settings.
- 21 May 2026
- Published by Frontiers Media SA in Frontiers in Bioinformatics
- Vol. 6, 1815548
Open AccessIntegrative transcriptomics and structure-based screening identifies Phyllanthus amarus phytocompounds as potential WNT5A modulators in ovarian cancer
Introduction: Ovarian cancer is one of the most lethal gynecological malignancies, largely due to its asymptomatic onset, heterogeneous molecular landscape, and frequent late-stage diagnosis. Identifying key oncogenic drivers and novel therapeutic candidates is important for understanding disease progression and guiding future research efforts. Methods: An integrative computational pipeline was employed to identify differentially expressed genes prioritize a candidate target, and screen plant compounds for anticancer potential. Transcriptomic datasets (GSE14407, GSE18520, and GSE26712) were retrieved from Gene Expression Omnibus and analyzed using GEO2R. The three-dimensional structure of WNT5A was obtained from AlphaFold. GC–MS profiling of Phyllanthus amarus Schumach. and Thonn. Identified phytocompounds for virtual screening, followed by molecular docking, ADME, and toxicity prediction. Molecular dynamics simulations, Free Energy Landscape and Dynamic Cross-Correlation Matrix analyses were performed. Further, Free energy perturbation (FEP) calculations were performed to estimate relative binding free energies across alchemical λ states. Results: A total of 103 consistently upregulated genes were identified, among which WNT5A emerged as a key regulator associated with tumor progression, metastasis, and chemoresistance. Enrichment analysis indicated involvement in mesenchymal development, extracellular matrix organization, and receptor-mediated signaling. GC–MS identified 48 compounds, and docking revealed several ligands with favorable interactions with WNT5A . MD simulations supported the structural stability of selected complexes, while FEL and DCCM analyses indicated stable conformational states and ligand-influenced residue dynamics. The FEP-derived free energy estimates further supported the stability and favorable binding of selected ligands toward WNT5A. These results enhance confidence in the computational predictions and complement the MD and docking analyses. Discussion: This integrative in silico framework highlights WNT5A as a potential therapeutic target and identifies bioactive compounds from P. amarus as candidates for further investigation. These findings provide preliminary computational insights and warrant experimental validation to improve treatment outcomes in healthcare settings.
- Open Access
- 20 May 2026
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 27 (10) , 4590
Targeting the Highly Deleterious G161C and Y260C SNP Variants of the AGXT Protein Involved in Glyoxylate Metabolism Using Tauroursodeoxycholic Acid: A Computational Study
Hyperoxaluria Type 1 (PH1) is a rare autosomal recessive metabolic disorder caused by mutations in the AGXT gene, leading to impaired glyoxylate metabolism and excessive oxalate accumulation, resulting in nephrolithiasis, nephrocalcinosis, and end-stage renal disease. As a rare and often neglected disease, PH1 poses a significant challenge to modern healthcare systems due to its progressive nature and limited therapeutic options. In this study, an integrated in silico approach was employed to identify pathogenic single-nucleotide polymorphisms (SNPs) and evaluate potential therapeutic candidates. Computational analyses using ConSurf, Align-GVGD, INPS-MD, CUPSAT, and iStable identified G161C and Y260C as highly deleterious variants affecting protein stability. Virtual screening, followed by ADME and toxicity assessments, identified Tauroursodeoxycholic acid (TUDCA) as a promising candidate with favorable pharmacokinetic and safety profiles. Molecular docking revealed that TUDCA exhibited higher binding affinity than the reference drug pyridoxine across native and SNP variants of AGXT proteins. Molecular dynamics simulations (300 ns) demonstrated enhanced structural stability of TUDCA-bound complexes, indicated by reduced RMSD and RMSF, improved compactness, and sustained hydrogen bonding. Furthermore, free energy landscape (FEL) and dynamic cross-correlation matrix (DCCM) analyses confirmed improved conformational stability and coordinated residue motions in SNP variant structures. Overall, these findings suggest that TUDCA may effectively stabilize structural alterations induced by pathogenic AGXT variants, highlighting its potential as a precision medicine-based therapeutic strategy for PH1.
- 20 May 2026
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 27 (10) , 4590
Open AccessTargeting the Highly Deleterious G161C and Y260C SNP Variants of the AGXT Protein Involved in Glyoxylate Metabolism Using Tauroursodeoxycholic Acid: A Computational Study
Hyperoxaluria Type 1 (PH1) is a rare autosomal recessive metabolic disorder caused by mutations in the AGXT gene, leading to impaired glyoxylate metabolism and excessive oxalate accumulation, resulting in nephrolithiasis, nephrocalcinosis, and end-stage renal disease. As a rare and often neglected disease, PH1 poses a significant challenge to modern healthcare systems due to its progressive nature and limited therapeutic options. In this study, an integrated in silico approach was employed to identify pathogenic single-nucleotide polymorphisms (SNPs) and evaluate potential therapeutic candidates. Computational analyses using ConSurf, Align-GVGD, INPS-MD, CUPSAT, and iStable identified G161C and Y260C as highly deleterious variants affecting protein stability. Virtual screening, followed by ADME and toxicity assessments, identified Tauroursodeoxycholic acid (TUDCA) as a promising candidate with favorable pharmacokinetic and safety profiles. Molecular docking revealed that TUDCA exhibited higher binding affinity than the reference drug pyridoxine across native and SNP variants of AGXT proteins. Molecular dynamics simulations (300 ns) demonstrated enhanced structural stability of TUDCA-bound complexes, indicated by reduced RMSD and RMSF, improved compactness, and sustained hydrogen bonding. Furthermore, free energy landscape (FEL) and dynamic cross-correlation matrix (DCCM) analyses confirmed improved conformational stability and coordinated residue motions in SNP variant structures. Overall, these findings suggest that TUDCA may effectively stabilize structural alterations induced by pathogenic AGXT variants, highlighting its potential as a precision medicine-based therapeutic strategy for PH1.
- Open Access
- 19 May 2026
- Published by American Chemical Society (ACS) in ACS Omega
- Vol. 11 (21) , 31812
Correction to “Computational Prediction of Deleterious SNPs in the GALNS Gene Implicated in Morquio A Syndrome (MPS IVA)”
[This corrects the article DOI: 10.1021/acsomega.5c07121.].
- 19 May 2026
- Published by American Chemical Society (ACS) in ACS Omega
- Vol. 11 (21) , 31812
Open AccessCorrection to “Computational Prediction of Deleterious SNPs in the GALNS Gene Implicated in Morquio A Syndrome (MPS IVA)”
[This corrects the article DOI: 10.1021/acsomega.5c07121.].
- Open Access
- 15 May 2026
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 27 (10) , 4404
Molecular Modeling of N-Acetylglucosamine Binding to the I154R Mutant of NAGLU: Pathogenic Insights into Sanfilippo Syndrome Type B
Sanfilippo syndrome type B, also known as mucopolysaccharidosis type IIIB (MPS IIIB), is a rare autosomal recessive lysosomal storage disorder caused by mutations in the N-acetyl-α-D-glucosaminidase (NAGLU) gene, which encodes the enzyme α-N-acetylglucosaminidase. This enzyme is essential for degrading heparan sulfate. The deficiency leads to toxic accumulation within cells. To investigate the impact of NAGLU mutations, mutational data were retrieved from public databases including NCBI, UniProt, and HGMD. A total of 162 variants were evaluated using sequence-based prediction tools to identify deleterious mutations, followed by structure-based in silico analyses to assess changes in protein stability, biophysical properties, and ligand-binding potential. Among the analyzed mutations, the I154R variant was identified as the most deleterious, showing disease-associated characteristics, structural instability, and impaired functional properties. Molecular docking with N-acetylglucosamine (NAG) revealed binding affinities of −4.17 kcal/mol for the native protein and −3.97 kcal/mol for the I154R mutant, suggesting a retained yet slightly reduced binding potential. Molecular dynamics simulations supported these findings, indicating stable trajectories, favorable interaction profiles, and moderate flexibility for both complexes. These results enhance our understanding of NAGLU-related pathogenicity in MPS IIIB, contributing to improved health care strategies and offering a valuable foundation for future therapeutic developments targeting enzyme dysfunction in Sanfilippo syndrome type B.
- 15 May 2026
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 27 (10) , 4404
Open AccessMolecular Modeling of N-Acetylglucosamine Binding to the I154R Mutant of NAGLU: Pathogenic Insights into Sanfilippo Syndrome Type B
Sanfilippo syndrome type B, also known as mucopolysaccharidosis type IIIB (MPS IIIB), is a rare autosomal recessive lysosomal storage disorder caused by mutations in the N-acetyl-α-D-glucosaminidase (NAGLU) gene, which encodes the enzyme α-N-acetylglucosaminidase. This enzyme is essential for degrading heparan sulfate. The deficiency leads to toxic accumulation within cells. To investigate the impact of NAGLU mutations, mutational data were retrieved from public databases including NCBI, UniProt, and HGMD. A total of 162 variants were evaluated using sequence-based prediction tools to identify deleterious mutations, followed by structure-based in silico analyses to assess changes in protein stability, biophysical properties, and ligand-binding potential. Among the analyzed mutations, the I154R variant was identified as the most deleterious, showing disease-associated characteristics, structural instability, and impaired functional properties. Molecular docking with N-acetylglucosamine (NAG) revealed binding affinities of −4.17 kcal/mol for the native protein and −3.97 kcal/mol for the I154R mutant, suggesting a retained yet slightly reduced binding potential. Molecular dynamics simulations supported these findings, indicating stable trajectories, favorable interaction profiles, and moderate flexibility for both complexes. These results enhance our understanding of NAGLU-related pathogenicity in MPS IIIB, contributing to improved health care strategies and offering a valuable foundation for future therapeutic developments targeting enzyme dysfunction in Sanfilippo syndrome type B.
- Open Access
- 14 May 2026
- Published by Frontiers Media SA in Frontiers in Oncology
- Vol. 16, 1770430
Integrated perspectives on colorectal carcinogenesis: molecular pathogenesis, genomic alterations, diagnostic paradigms, therapeutic interventions and AI–driven directions in precision oncology
Colorectal cancer (CRC) remains a leading cause of cancer-related morbidity and mortality worldwide, with a notable rise in incidence among younger populations and in developing nations. This review provides an integrative perspective on the molecular pathogenesis, epidemiology, classification, diagnosis, and therapeutic strategies in CRC. We emphasize the pivotal role of three major molecular pathways - chromosomal instability (CIN), microsatellite instability (MSI), and CpG island methylator phenotype (CIMP) and their association with tumor heterogeneity and clinical outcomes. The analysis highlights key risk factors including lifestyle-related variables and genetic predisposition, alongside emerging molecular subtypes that influence prognosis and therapeutic decision-making. Advances in non-invasive diagnostics, such as fecal immunochemical testing (FIT) and novel biomarker discovery, demonstrate potential for improving early detection and screening compliance. Preventive strategies encompassing lifestyle modification, chemoprevention, and vitamin D supplementation, coupled with tailored therapeutic interventions including monoclonal antibodies and targeted therapies, offer promising avenues for reducing disease burden. The review also explores recent advances in multi-omics integration and artificial intelligence driven analytics, which have transformed biomarker discovery, subtype classification, and therapeutic prediction in CRC. Emerging applications of machine learning (ML), radiogenomics, and quantum computing further highlight a paradigm shift toward precision oncology. This review underscores the need for precision oncology approaches that integrate molecular profiling, patient stratification, and personalized treatment to enhance health care delivery and clinical outcomes in CRC.
- 14 May 2026
- Published by Frontiers Media SA in Frontiers in Oncology
- Vol. 16, 1770430
Open AccessIntegrated perspectives on colorectal carcinogenesis: molecular pathogenesis, genomic alterations, diagnostic paradigms, therapeutic interventions and AI–driven directions in precision oncology
Colorectal cancer (CRC) remains a leading cause of cancer-related morbidity and mortality worldwide, with a notable rise in incidence among younger populations and in developing nations. This review provides an integrative perspective on the molecular pathogenesis, epidemiology, classification, diagnosis, and therapeutic strategies in CRC. We emphasize the pivotal role of three major molecular pathways - chromosomal instability (CIN), microsatellite instability (MSI), and CpG island methylator phenotype (CIMP) and their association with tumor heterogeneity and clinical outcomes. The analysis highlights key risk factors including lifestyle-related variables and genetic predisposition, alongside emerging molecular subtypes that influence prognosis and therapeutic decision-making. Advances in non-invasive diagnostics, such as fecal immunochemical testing (FIT) and novel biomarker discovery, demonstrate potential for improving early detection and screening compliance. Preventive strategies encompassing lifestyle modification, chemoprevention, and vitamin D supplementation, coupled with tailored therapeutic interventions including monoclonal antibodies and targeted therapies, offer promising avenues for reducing disease burden. The review also explores recent advances in multi-omics integration and artificial intelligence driven analytics, which have transformed biomarker discovery, subtype classification, and therapeutic prediction in CRC. Emerging applications of machine learning (ML), radiogenomics, and quantum computing further highlight a paradigm shift toward precision oncology. This review underscores the need for precision oncology approaches that integrate molecular profiling, patient stratification, and personalized treatment to enhance health care delivery and clinical outcomes in CRC.